Literature DB >> 16508756

Activated protein C: do more survive?

William L Macias.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16508756     DOI： 10.1007/s00134-006-0087-8

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  11 in total

1.  Data safety and monitoring boards.

Authors:  Arthur S Slutsky; James V Lavery
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

2.  Activated protein C: do more survive?

Authors:  Alasdair F Mackenzie
Journal:  Intensive Care Med       Date:  2005-10-15       Impact factor: 17.440

3.  The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.

Authors:  Derek C Angus; Pierre-Francois Laterre; Jeff Helterbrand; E Wesley Ely; Daniel E Ball; Rekha Garg; Lisa A Weissfeld; Gordon R Bernard
Journal:  Crit Care Med       Date:  2004-11       Impact factor: 7.598

4.  Efficacy and safety of recombinant human activated protein C for severe sepsis.

Authors:  G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

5.  Subgroup analysis and other (mis)uses of baseline data in clinical trials.

Authors:  S F Assmann; S J Pocock; L E Enos; L E Kasten
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

6.  Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.

Authors:  Jean-Louis Vincent; Derek C Angus; Antonio Artigas; Andre Kalil; Bruce R Basson; Hassan H Jamal; Gerald Johnson; Gordon R Bernard
Journal:  Crit Care Med       Date:  2003-03       Impact factor: 7.598

7.  Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

Authors:  Edward Abraham; Pierre-François Laterre; Rekha Garg; Howard Levy; Deepak Talwar; Benjamin L Trzaskoma; Bruno François; Jeffrey S Guy; Martina Brückmann; Alvaro Rea-Neto; Rolf Rossaint; Dominique Perrotin; Armin Sablotzki; Nancy Arkins; Barbara G Utterback; William L Macias
Journal:  N Engl J Med       Date:  2005-09-29       Impact factor: 91.245

8.  Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials.

Authors:  S Yusuf; J Wittes; J Probstfield; H A Tyroler
Journal:  JAMA       Date:  1991-07-03       Impact factor: 56.272

9.  Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis.

Authors:  Jerry A Nick; Christopher D Coldren; Mark W Geraci; Katie R Poch; Brian W Fouty; James O'Brien; Michael Gruber; Simona Zarini; Robert C Murphy; Katherine Kuhn; Don Richter; Kelly R Kast; Edward Abraham
Journal:  Blood       Date:  2004-08-31       Impact factor: 22.113

10.  Effects of drotrecogin alfa (activated) in human endotoxemia.

Authors:  Andre C Kalil; Susette M Coyle; John Y Um; Steven P LaRosa; Mary Ann Turlo; Steve E Calvano; David P Sundin; David R Nelson; Stephen F Lowry
Journal:  Shock       Date:  2004-03       Impact factor: 3.454
View more
  1 in total

1.  Drotrecogin alfa in tropical infections and refractory multi-organ failure.

Authors:  Farhad Kapadia; Charudatt Shirwadkar
Journal:  Intensive Care Med       Date:  2006-06-02       Impact factor: 17.440
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.